Status:

COMPLETED

A Study To Test The Effect Of GW786034 (Pazopanib) On P450 Enzymes

Lead Sponsor:

GlaxoSmithKline

Conditions:

Carcinoma, Renal Cell

Eligibility:

All Genders

21+ years

Phase:

PHASE1

Brief Summary

This is a Phase I study to determine the effect of GW786034 (pazopanib) on P450 enzymes. This study will help determine which types of drugs may interact with GW786034.

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Histologically or cytologically confirmed diagnosis of advanced solid tumors.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Adequate bone marrow, renal, lung, and liver function.
  • A female subject must not be pregnant and will agree not to become pregnant during the trial
  • Exclusion criteria:
  • Any major surgery, chemotherapy, hormone therapy, investigational drugs, or radiotherapy within the last 28 days.
  • Poorly controlled hypertension.
  • Corrected QT (QTc) prolongation defined as a QTc interval greater than or equal to 480 msec and a prior history of cardiovascular disease, arrhythmias, or significant ECG abnormalities.
  • Arterial or venous thrombi (including cerebrovascular accident), myocardial infarction, admission for unstable angina, cardiac angioplasty, or stenting within the last 3 months.
  • Current use of therapeutic anticoagulation (low molecular weight heparin, oral anticoagulant agents).
  • Amiodarone must not have been taken for at least 6 months prior to the administration of the first dose of study drug.
  • History of brain metastases.
  • Has narrow-angle glaucoma which is a contraindication to midazolam use.
  • History of nicotine-containing product (including cigarettes, cigars, nicotine patches) use within the past 6 months.
  • A history of bleeding problems.

Exclusion

    Key Trial Info

    Start Date :

    July 28 2006

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    February 20 2008

    Estimated Enrollment :

    24 Patients enrolled

    Trial Details

    Trial ID

    NCT00401583

    Start Date

    July 28 2006

    End Date

    February 20 2008

    Last Update

    November 13 2017

    Active Locations (2)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (2 locations)

    1

    GSK Investigational Site

    Lebanon, New Hampshire, United States, 03756

    2

    GSK Investigational Site

    Singapore, Singapore, 119074